Vertex Pharmaceuticals Incorporated (LON:0QZU)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 94.74B |
| Revenue (ttm) | 8.80B |
| Net Income (ttm) | -427.82M |
| Shares Out | n/a |
| EPS (ttm) | -1.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 917 |
| Average Volume | 577 |
| Open | 488.99 |
| Previous Close | 490.14 |
| Day's Range | 486.16 - 492.61 |
| 52-Week Range | 290.87 - 492.61 |
| Beta | 0.51 |
| RSI | 51.05 |
| Earnings Date | May 5, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
On CNBC's “Halftime Report Final Trades ,” Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc . (NASDAQ: CRWD). On Wednesday, CrowdStrike announced an expansion of its partne...
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner Internati...
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike
The Investment Committee give you their top stocks to watch in this volatile markets.
GreensKeeper Q1 2025 Portfolio Update
Berkshire Hathaway led Q1 with a 17.5% return, driven by strong operating earnings and potential for significant acquisitions with over $300 billion in cash. Vertex Pharmaceuticals gained 20.4%, fuele...
Is Vertex Pharmaceuticals Stock a Buy?
European Commission Expands Approval for Vertex's Kaftrio (VRTX)
European Commission Expands Approval for Vertex's Kaftrio (VRTX)
Vertex to Announce First Quarter 2025 Financial Results on May 5th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company w...
Vertex Pharmaceuticals gets EU nod to expand label for cystic fibrosis treatment
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx . Journavx Gains Early Traction At ...
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx.
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elex...
Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our recommendation for VRTX stock.
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 clinical trials. Vertex p...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Vertex Pharmaceuticals (VRTX) Halts VX-264 Development, Incurs $400M Impairment
Vertex Pharmaceuticals (VRTX) Halts VX-264 Development, Incurs $400M Impairment
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollm...
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC's “Halftime Report Final Trades ,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). RB...
Final Trades: Vertex Pharma, Netflix and the IYF
The Investment Committee give you their stop stocks to watch for the second half.
Final Trades: Vertex Pharma, Netflix and the IYF
The Investment Committee give you their stop stocks to watch for the second half.
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBCs Halftime Report to explain why he's buying the Pharmaceutical company